NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/05/2022
Back to search
Official data from USPTO
EXCIVA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
66
Latest update
07/05/2022
Trademark type
Word
Nice classes
5
Filing date
10/06/2016
Registration date
07/05/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/05/2022
Last transaction
07/05/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
07/02/2018
First use in commerce
07/02/2018
Drawing code
4
Owner type
16
Owner location
Vernon Hills, IL
Examiner
HARMON, RAYMOND E
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
EXCIVA LLC
EXCIVA UG (haftungsbeschränkt)
EXCIVA UG (haftungsbeschränkt)
Representatives
SREENIVASARAO VEPACHEDU EXCIVA LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctionhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; for the treatment of inflammatory disorders; for use in dermatologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesfor the treatment of bacteria-based diseasesfor the treatment of diabetesanti - infective preparationsantiviral preparationsantibioticsantifungal preparations and vaccines; Pharmaceutical preparations for the prevention of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS)peripheral nerve disordersmentalneurologicalpsychologicalpsychosomaticposttraumatic stressalcoholnicotinedrug dependence related diseasesdisorders and conditions; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS)peripheral nerve disordersmentalneurologicalpsychologicalpsychosomaticposttraumatic stressalcoholnicotinedrug dependence related diseasesdisorders and conditions; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS)peripheral nerve disordersmentalneurologicalpsychologicalpsychosomaticposttraumatic stressalcoholnicotinedrug dependence related diseasesdisorders and conditions; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorderssports related injuriesfor knee cartilage regeneration; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS)peripheral nerve disordersmentalneurologicalpsychologicalpsychosomaticposttraumatic stressalcoholnicotinedrug dependence related diseasesdisorders and conditions; Pharmaceutical preparationsa blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparationsa topical preparation for the treatment of ocular disorders prescribed by ophthalmologistseye surgeonsoptometrists; Pharmaceutical preparationsan analgesic for human consumption taken orally; Pharmaceutical preparationsanticoagulants; Pharmaceutical preparationsantidepressants; Pharmaceutical preparationsappetite suppressants; Pharmaceutical preparationsdantrolene sodium for injection; Pharmaceutical preparationselixirs for the treatment of disorders of the nervous system including central nervous system (CNS) and peripheral nervous system (PNS)peripheral nerve disordersmentalneurologicalpsychologicalpsychosomaticposttraumatic stressalcoholnicotinedrug dependence related diseasesdisorders and conditions; Pharmaceutical preparationsinjectable contraceptives; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for chloasma; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticalsanti-infectives; Pharmaceuticalsantihelmintics; Pharmaceuticalsinducers of erections; Pharmaceuticalslipid lowering agents; Pharmaceuticalspsychotropics; Preparations for the suppression of hormones; Preparations for the treatment of asthma; Preparations for the treatment of burns; Preparations for treating colds; Preparations in the form of granules and liquids for controlling and removing moss; Preparations in the form of powders for controlling and removing moss; Preparations to destroy mildew; Preparations to prevent chewing or biting by animals; Preparations to prevent nail-biting and thumb-sucking; Prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachets and pharmaceutical preparations for the treatment of cardiovascular disorders
Publications
History of USPTO decisions and trademark events.
66 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
07/05/2022
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/02/2022
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/01/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/01/2022
ALIE
ASSIGNED TO LIE
05/28/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/25/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/15/2022
GNFR
FINAL REFUSAL E-MAILED
02/15/2022
CNFR
SU - FINAL REFUSAL - WRITTEN
02/15/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/20/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/20/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/07/2021
GNRT
NON-FINAL ACTION E-MAILED
10/07/2021
CNRT
SU - NON-FINAL ACTION - WRITTEN
10/07/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/14/2021
IURF
IU INFORMAL RESPONSE RECEIVED
08/31/2021
EISU
TEAS STATEMENT OF USE RECEIVED
08/31/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/31/2021
IUFF
USE AFFIDAVIT FAILED FORMALITIES
08/31/2021
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
08/28/2021
INCS
ITU OFFICE ACTION ISSUED FOR STATEMENT OF USE
08/28/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/28/2021
IUAF
USE AMENDMENT FILED
08/25/2021
EISU
TEAS STATEMENT OF USE RECEIVED
08/25/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/11/2021
TMBN
TTAB RELEASE CASE TO TRADEMARKS
03/29/2021
OP.T
OPPOSITION TERMINATED NO. 999999
03/29/2021
TTCD
BOARD DECISION COUNTERCLAIM DENIED
03/29/2021
DOCK
ASSIGNED TO EXAMINER
03/29/2021
OP.D
OPPOSITION DISMISSED NO. 999999
03/25/2021
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/29/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/05/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/05/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/05/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/05/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/05/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
08/07/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/03/2018
OP.I
OPPOSITION INSTITUTED NO. 999999
01/17/2018
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
10/17/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/27/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/26/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/19/2017
PUBO
PUBLISHED FOR OPPOSITION
09/19/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/30/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/24/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/24/2017
ALIE
ASSIGNED TO LIE
07/18/2017
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/11/2017
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/26/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/01/2017
GNFR
FINAL REFUSAL E-MAILED
05/01/2017
CNFR
FINAL REFUSAL WRITTEN
05/01/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/27/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/27/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/27/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/14/2017
GNRT
NON-FINAL ACTION E-MAILED
01/14/2017
CNRT
NON-FINAL ACTION WRITTEN
01/14/2017
DOCK
ASSIGNED TO EXAMINER
01/13/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/13/2016
NWAP
NEW APPLICATION ENTERED
10/10/2016
Continuous trademark protection
Get notified about every new filing that threatens EXCIVA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.